Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 91.3%

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 419,700 shares, a growth of 91.3% from the March 31st total of 219,400 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 193,600 shares, the days-to-cover ratio is presently 2.2 days.

TScan Therapeutics Stock Performance

Shares of TCRX traded up $0.03 during mid-day trading on Friday, hitting $7.32. The company's stock had a trading volume of 92,052 shares, compared to its average volume of 210,320. The firm has a market capitalization of $350.50 million, a PE ratio of -3.87 and a beta of 0.90. TScan Therapeutics has a one year low of $1.62 and a one year high of $9.00. The stock's 50-day moving average is $7.19 and its two-hundred day moving average is $5.83. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $7.21 million during the quarter, compared to analysts' expectations of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. As a group, sell-side analysts anticipate that TScan Therapeutics will post -1.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TCRX shares. Wedbush reissued an "outperform" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Tuesday. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Thursday, March 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pale Fire Capital SE bought a new position in TScan Therapeutics in the third quarter worth $42,000. Letko Brosseau & Associates Inc. acquired a new position in TScan Therapeutics during the third quarter worth $83,000. Cannon Global Investment Management LLC acquired a new position in TScan Therapeutics during the first quarter worth $139,000. Finally, abrdn plc acquired a new position in TScan Therapeutics during the fourth quarter worth $1,166,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.